GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

Shingrix pulled in sales of £2 billion (around $2.8 billion) last year from its current indication in the prevention of shingles in the over-50s age group but GSK reckons that younger immune ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter ... Killers:' How Memecoins Teach A 'Skill To Succeed' In Crypto Shingrix, a vaccine against herpes zoster (shingles), grew 17% in the full ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...